Tags

Type your tag names separated by a space and hit enter

Expression of adiponectin and its receptors in livers of morbidly obese patients with non-alcoholic fatty liver disease.
J Gastroenterol Hepatol 2009; 24(2):233-7JG

Abstract

BACKGROUND AND AIM

Obesity is one of the risk factors for non-alcoholic fatty liver disease (NAFLD) and a common disease that comprises simple steatosis and non-alcoholic steatohepatitis (NASH), and can eventually lead to liver cirrhosis. Adiponectin is an adipocyte-derived protein that has anti-obesity, antidiabetic and anti-inflammatory properties, and is considered to possess a hepatoprotective function. Its role in the development and progression of NAFLD in morbidly obese patients is unknown. In this study, we examined the expression levels of adiponectin and its receptors in liver biopsies of morbidly obese patients and then determined whether there was an association with the disease severity.

METHODS

Liver biopsies from 30 morbidly obese patients (18 NASH vs 12 steatosis) were analyzed. The needle core biopsies were subjected to routine histological examination and stained immunohistochemically for adiponectin, adiponectin receptor I (adipoRI) and receptor II (adipoRII).

RESULTS

The two groups were comparable with respect to body mass index, age and gender distribution. The expression of adiponectin decreased in liver biopsies with NASH as compared to those with simple steatosis (1.61 +/- 0.70 vs 2.25 +/- 0.75, P = 0.028). Spearman's rank correlation coefficient analysis showed that the staining intensity of adiponectin negatively correlated with the grade of inflammation (r = -0.368, P = 0.045) and stage of fibrosis (r = -0.380, P = 0.038). There was no significant difference in expression of adipoRI and adipoRII between the two groups.

CONCLUSION

These findings indicate that decreased liver adiponectin expression may play a role in the development and progression of NAFLD, from simple steatosis to NASH, in morbidly obese patients.

Authors+Show Affiliations

Department of Endocrinology, Zhongshan Hospital Xiamen University, Xiamen, Fujian, China. mah-169@163.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

18713296

Citation

Ma, Hong, et al. "Expression of Adiponectin and Its Receptors in Livers of Morbidly Obese Patients With Non-alcoholic Fatty Liver Disease." Journal of Gastroenterology and Hepatology, vol. 24, no. 2, 2009, pp. 233-7.
Ma H, Gomez V, Lu L, et al. Expression of adiponectin and its receptors in livers of morbidly obese patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2009;24(2):233-7.
Ma, H., Gomez, V., Lu, L., Yang, X., Wu, X., & Xiao, S. Y. (2009). Expression of adiponectin and its receptors in livers of morbidly obese patients with non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology, 24(2), pp. 233-7. doi:10.1111/j.1440-1746.2008.05548.x.
Ma H, et al. Expression of Adiponectin and Its Receptors in Livers of Morbidly Obese Patients With Non-alcoholic Fatty Liver Disease. J Gastroenterol Hepatol. 2009;24(2):233-7. PubMed PMID: 18713296.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Expression of adiponectin and its receptors in livers of morbidly obese patients with non-alcoholic fatty liver disease. AU - Ma,Hong, AU - Gomez,Victoria, AU - Lu,Liang, AU - Yang,Xiangjiu, AU - Wu,Xiaoyan, AU - Xiao,Shu-Yuan, Y1 - 2008/08/17/ PY - 2008/8/21/pubmed PY - 2009/5/8/medline PY - 2008/8/21/entrez SP - 233 EP - 7 JF - Journal of gastroenterology and hepatology JO - J. Gastroenterol. Hepatol. VL - 24 IS - 2 N2 - BACKGROUND AND AIM: Obesity is one of the risk factors for non-alcoholic fatty liver disease (NAFLD) and a common disease that comprises simple steatosis and non-alcoholic steatohepatitis (NASH), and can eventually lead to liver cirrhosis. Adiponectin is an adipocyte-derived protein that has anti-obesity, antidiabetic and anti-inflammatory properties, and is considered to possess a hepatoprotective function. Its role in the development and progression of NAFLD in morbidly obese patients is unknown. In this study, we examined the expression levels of adiponectin and its receptors in liver biopsies of morbidly obese patients and then determined whether there was an association with the disease severity. METHODS: Liver biopsies from 30 morbidly obese patients (18 NASH vs 12 steatosis) were analyzed. The needle core biopsies were subjected to routine histological examination and stained immunohistochemically for adiponectin, adiponectin receptor I (adipoRI) and receptor II (adipoRII). RESULTS: The two groups were comparable with respect to body mass index, age and gender distribution. The expression of adiponectin decreased in liver biopsies with NASH as compared to those with simple steatosis (1.61 +/- 0.70 vs 2.25 +/- 0.75, P = 0.028). Spearman's rank correlation coefficient analysis showed that the staining intensity of adiponectin negatively correlated with the grade of inflammation (r = -0.368, P = 0.045) and stage of fibrosis (r = -0.380, P = 0.038). There was no significant difference in expression of adipoRI and adipoRII between the two groups. CONCLUSION: These findings indicate that decreased liver adiponectin expression may play a role in the development and progression of NAFLD, from simple steatosis to NASH, in morbidly obese patients. SN - 1440-1746 UR - https://www.unboundmedicine.com/medline/citation/18713296/Expression_of_adiponectin_and_its_receptors_in_livers_of_morbidly_obese_patients_with_non_alcoholic_fatty_liver_disease_ L2 - https://doi.org/10.1111/j.1440-1746.2008.05548.x DB - PRIME DP - Unbound Medicine ER -